Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
25 hedge funds and large institutions have $35.3M invested in Oncternal Therapeutics, Inc. Common Stock in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
71% more capital invested
Capital invested by funds: $20.7M → $35.3M (+$14.6M)
25% more funds holding
Funds holding: 20 → 25 (+5)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.36M |
| 2 |
Millennium Management
New York
|
+$610K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$515K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$447K |
| 5 |
Barclays
London,
United Kingdom
|
+$81.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FHA
First Horizon Advisors
Memphis,
Tennessee
|
-$66.6K |
| 2 |
JP Morgan Chase
New York
|
-$31.9K |
| 3 |
IA
IFP Advisors
Tampa,
Florida
|
-$13K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$13K |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$10.1K |
ONCT Hedge Fund Activity: Q4 2017 in Review
25 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2017, worth a combined $35.3M — up 71% from $20.7M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ONCT positions and 1 closed out — a net gain of 5 holders — while 4 added to existing stakes and 6 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.36M. The largest seller was First Horizon Advisors, cutting an estimated $66.6K.
- 25 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2017, up from 20 in Q3 2017.
- Funds reported $35.3M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2017, up 71% quarter-over-quarter.
- 6 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2017 and 1 closed out, a net change of +5 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2017 was Vanguard Group, an estimated $1.36M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2017 was First Horizon Advisors, an estimated $66.6K sold.
Based on aggregated 13F filings for Q4 2017.